公开(公告)号：US09108981B2

公开(公告)日：2015-08-18

申请号：US14528168

申请日：2014-10-30

Applicant: Bristol-Myers Squibb Company

Inventor： Patrick Y. S. Lam ,  Charles G. Clark ,  James R. Corte ,  William R. Ewing ,  Paul J. Gilligan ,  Yoon Jeon ,  Wu Yang ,  Leon M. Smith, II ,  Yufeng Wang

IPC: C07D498/06 ,  C07D471/06 ,  C07D487/06 ,  C07D498/08 ,  C07D471/08 ,  C07D487/08

CPC classification number: C07D498/08 ,  C07D471/06 ,  C07D471/08 ,  C07D487/06 ,  C07D487/08 ,  C07D498/06

Abstract: The present invention provides compounds of Formula (Ia): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.

Abstract translation: 本发明提供式（Ia）化合物或其立体异构体，互变异构体或其药学上可接受的盐，其中所有变量如本文所定义。 这些化合物是选择性因子XIa抑制剂或FXIa和血浆激肽释放酶的双重抑制剂。 本发明还涉及包含这些化合物的药物组合物和使用其制备血栓栓塞和/或炎症性疾病的方法。

公开(公告)号：US09540323B2

公开(公告)日：2017-01-10

申请号：US14418023

申请日：2013-07-30

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Alexandre L'Heureux ,  Sheldon Hiebert ,  Carol Hu ,  Patrick Y. S. Lam ,  John Lloyd ,  Zulan Pi ,  Jennifer X. Qiao ,  Carl Thibeault ,  George O. Tora ,  Wu Yang ,  Yufeng Wang ,  Tammy C. Wang ,  Michael S. Bowsher ,  Ruel Rejean

IPC: C07D209/26 ,  C07D401/04 ,  C07D401/12 ,  C07D403/04 ,  C07D403/14 ,  C07D409/04 ,  C07D413/04 ,  C07D417/12 ,  C07D417/14 ,  C07D471/04 ,  C07D498/04 ,  C07D209/14 ,  C07D513/04 ,  C07D403/12 ,  C07D413/14 ,  C07D417/04

CPC classification number: C07D209/26 ,  C07D209/14 ,  C07D401/04 ,  C07D401/12 ,  C07D403/04 ,  C07D403/12 ,  C07D403/14 ,  C07D409/04 ,  C07D413/04 ,  C07D413/14 ,  C07D417/04 ,  C07D417/12 ,  C07D417/14 ,  C07D471/04 ,  C07D498/04 ,  C07D513/04

Abstract: The present invention provides compounds of Formula (I): Formula (I) as defined in the specification and compositions comprising any of such novel compounds. These compounds are antagonists of P2Y1 receptor which may be used medicaments.

Abstract translation: 本发明提供式（I）化合物：如说明书中所定义的式（I）和包含任何这些新化合物的组合物。 这些化合物是可以使用药物的P2Y1受体的拮抗剂。

公开(公告)号：US09428504B2

公开(公告)日：2016-08-30

申请号：US14418011

申请日：2013-07-30

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Carl Thibeault ,  Charles G. Clark ,  Indawati DeLucca ,  Carol Hui Hu ,  Yoon Jeon ,  Patrick Y. S. Lam ,  Jennifer X. Qiao ,  Wu Yang ,  Yufeng Wang ,  Tammy C. Wang

IPC: C07D471/10 ,  C07D519/00

CPC classification number: C07D471/10 ,  C07D519/00

Abstract: The present invention provides compounds of Formula (I): as defined in the specification and compositions comprising any of such novel compounds. These compounds are antagonists of P2Y1 receptor and may be used as medicaments in the treatment and/or prophylaxis of thromboembolic disorders.